SCHEMBL15958538

SCHEMBL15958538

CCCC(c1ccc(C(=O)NCCC(=O)O)cc1)C(COc1ccc(-c2ccc(C)cc2)cc1)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.53
GCGR P47871 14/20 0.52
GCG P01275 5/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15958537 0.97 NPC1 (0.56) NPC1GCGRGCG
SCHEMBL2669862 0.93 GCGR (0.50) GCGRGCG
SCHEMBL15958534 0.89 GCG (0.53) NPC1GCGRGCG
SCHEMBL15948158 0.86 GCGR (0.60) GCGR
SCHEMBL2669963 0.84 GCGR (0.55) GCGRGCG
SCHEMBL15958539 0.84 GCGR (0.53) NPC1GCGRGCG
SCHEMBL15958542 0.84 UTS2R (0.42) NPC1GCGR
SCHEMBL15958536 0.81 NPC1 (0.46) NPC1GCGRGCG
SCHEMBL15958513 0.81 GCGR (0.56) GCGRGCG
SCHEMBL9071524 0.81 GCGR (0.53) GCGRGCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809579-B2 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use MERCK SHARP & DOHME CORP. (US) 2014-08-19 US disclosed
US-20110312911-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME CORP. 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312911-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE GCGR, GLP1R, GPR119 NPC1 1918/4885GCGR 1/4885GCG 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.